Abstract:Objective This paper describes the implementation of preemptive clinical pharmacogenomics (PGx) testing linked to an automated electronic clinical decision support (CDS) system delivering clinically actionable PGx information to clinicians at the point of care at UCSF Health, a large Academic Medical Center. Methods A multidisciplinary team developed the strategic vision for the PGx program. The drug-gene interactions of interest were compiled, and actionable alleles were identified. A genotyping platform was selected and validated at the in-house laboratory. Following HIPAA protocols, genotype results were electronically transferred and stored in EPIC. CDS was developed and integrated with electronic prescribing. Results We developed a customized clinical PGx program for 56 medications and 15 genes. 233 MWs and 15 BPAs, approved by clinicians, were built into EPIC to deliver actionable clinical PGx information to clinicians. Conclusions Our multidisciplinary team successfully implemented preemptive PGx testing linked to point-of-care electronic CDS to guide clinicians with precise medication decision-making.

What problem does this paper attempt to address?

This paper aims to solve the problem of how to implement pre - clinical pharmacogenomics (PGx) testing in a large - scale academic medical center - UCSF Health (University of California, San Francisco Health), and combine it with an automated electronic clinical decision - support (CDS) system to provide actionable PGx information to physicians at clinical decision - making points. Specifically, the research team's goals are: 1. **Develop a customized clinical PGx program**: For 56 drugs and 15 genes, establish a system that can provide accurate drug - decision support. 2. **Integrate a multidisciplinary team**: Formed an interdisciplinary team consisting of 23 members, covering experts in bioinformatics, hospital operations, PGx, electronic health record (EHR) usability, software engineering, laboratory operations, clinical education, billing, and clinicians. 3. **Identify drug - gene interactions**: Based on the recommendations of CPIC and FDA, determined the drug - gene interactions with the highest level of evidence, and finally determined the drug list at the start of the project. 4. **Select and validate a genotyping platform**: Selected ThermoFisher Scientific's PharmacoScan™ array for genotyping of target SNPs, and validated it according to CLIA standards, ensuring high sensitivity and specificity. 5. **Develop best - practice recommendations and drug - interaction warnings**: Developed 233 best - practice recommendations (BPAs) and 15 drug - interaction warnings (MWs) in APeX of the Epic system, and these alerts provide actionable PGx information at clinical decision - making points. 6. **Develop patient - specific PGx laboratory reports**: Designed easy - to - share PDF reports that clearly show the patient's genetic variations and their potential impact on drug treatment. 7. **Create educational content**: Developed educational materials for patients and clinicians to improve their understanding and application ability of PGx. Through the above measures, the research team has successfully implemented a pre - PGx testing project in UCSF Health, which is integrated with a point - of - care automated electronic CDS system, aiming to improve patient health outcomes and provider experiences.

CLINICAL IMPLEMENTATION OF PREEMPTIVE PHARMACOGENOMICS TESTING FOR PERSONALIZED MEDICINE AT AN ACADEMIC MEDICAL CENTER